{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:40:39Z","timestamp":1790458839287,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40257-019-00454-6","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T10:02:57Z","timestamp":1560765777000},"page":"725-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long-Term Effectiveness and Safety of Up to 48 Weeks\u2019 Treatment with Topical Adapalene 0.3%\/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne"],"prefix":"10.1007","volume":"20","author":[{"given":"Brigitte","family":"Dr\u00e9no","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Gagn\u00e9-Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Barankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Kerrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"issue":"3","key":"454_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1525-1470.1991.tb00856.x","volume":"8","author":"JY Koo","year":"1991","unstructured":"Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol. 1991;8(3):185\u20138 (Review).","journal-title":"Pediatr Dermatol."},{"issue":"2 Suppl 1","key":"454_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","volume":"78","author":"DM Thiboutot","year":"2018","unstructured":"Thiboutot DM, Dr\u00e9no B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1\u201323.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"454_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40257-016-0178-4","volume":"17","author":"L Stein Gold","year":"2016","unstructured":"Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3%\/benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293\u2013303.","journal-title":"Am J Clin Dermatol."},{"issue":"4","key":"454_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.14026","volume":"31","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Tan J, Rivier M, Martel P, Bissonnette R. Adapalene 0.1%\/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31(4):737\u201342.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"454_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-018-0352-y","volume":"19","author":"B Dr\u00e9no","year":"2018","unstructured":"Dr\u00e9no B, Bissonnette R, Gagn\u00e9-Henley A, Barankin B, Lynde C, Kerrouche N, et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%\/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison. Am J Clin Dermatol. 2018;19(2):275\u201386.","journal-title":"Am J Clin Dermatol."},{"key":"454_CR6","unstructured":"Galderma. Adapalene 0.3% - benzoyl peroxide 2.5% gel and risk of formation of atrophic acne scars (OSCAR) [ClinicalTrials.gov identifier NCT02735421]. US National Institutes of Health, ClinicalTrials.gov. \n                    https:\/\/www.clinicaltrials.gov\n                    \n                  . Accessed 21 May 2019."},{"issue":"2","key":"454_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13555-018-0231-8","volume":"8","author":"MJ Loss","year":"2018","unstructured":"Loss MJ, Leung S, Chien A, Kerrouche N, Fischer AH, Kang S. Adapalene 0.3% gel shows efficacy for the treatment of atrophic acne scars. Dermatol Ther (Heidelb). 2018;8(2):245\u201357.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"454_CR8","first-page":"566","volume":"16","author":"J Tan","year":"2017","unstructured":"Tan J, Bourd\u00e8s V, Bissonnette R, Petit B, Eng L, Reynier P, et al. Prospective study of pathogenesis of atrophic acne scars and role of macular erythema. J Drugs Dermatol. 2017;16(6):566\u201372.","journal-title":"J Drugs Dermatol."},{"issue":"12","key":"454_CR9","first-page":"1427","volume":"14","author":"J Weiss","year":"2015","unstructured":"Weiss J, Stein Gold L, Leoni M, Rueda MJ, Liu H, Tanghetti E. Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment\u2014adapalene 0.3%-benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2015;14(12):1427\u201335.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"454_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/j.1365-2133.2011.10344.x","volume":"164","author":"Y Poulin","year":"2011","unstructured":"Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol. 2011;164(6):1376\u201382.","journal-title":"Br J Dermatol."},{"issue":"2","key":"454_CR11","first-page":"174","volume":"11","author":"J Tan","year":"2012","unstructured":"Tan J, Stein Gold L, Schlessinger J, Brodell R, Jones T, Cruz A, et al. Short-term combination therapy and long-term relapse prevention in the treatment of severe acne vulgaris. J Drugs Dermatol. 2012;11(2):174\u201380.","journal-title":"J Drugs Dermatol."},{"issue":"10","key":"454_CR12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/jdv.14379","volume":"31","author":"A Bouloc","year":"2017","unstructured":"Bouloc A, Roo E, Imko-Walczuk B, Moga A, Chadoutaud B, Dr\u00e9no B. A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. J Eur Acad Dermatol Venereol. 2017;31(10):1727\u201331.","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00454-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T23:08:22Z","timestamp":1592262502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00454-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"17 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Galderma R&D.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The investigators (BD, RB, AG-H, BB, CL, JT) received financial support for conducting the study. Dr B. Dr\u00e9no has been an investigator and\/or consultant for Bioderma, Galderma, Pierre Fabre, and La Roche Posay. Dr R. Bissonnette has been an investigator, consultant, advisory board member, and speaker for BioPharmX, Cipher, Dermira, Galderma, GSK-Stiefel, Valeant, and Xenon and is a shareholder of Innovaderm Research. Dr A. Gagn\u00e9-Henley has been an investigator, consultant, advisory board member, and\/or speaker for Abbvie, Celgene, Dignity, Galderma, Janssen, Leo Pharma, Novartis, Sanofi, Valeant, and Xenon. Dr B. Barankin has been a consultant and speaker for Galderma. Dr C. Lynde has been a consultant, advisory board member, and speaker for Bayer, Galderma, GSK, and Valeant. Dr J. Tan has been an investigator, consultant, advisory board member, and speaker, and has provided expert testimony, for Galderma. Dr R. Chavda is an employee of Galderma and Mr N. Kerrouche is a previous employee of Galderma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with the International Conference on Harmonization-Good Clinical Practice and local regulatory requirements. The study was reviewed and approved by the appropriate Independent Ethics Committees, and written informed consent was obtained from all subjects prior to study initiation. Additional informed consent was obtained from all individual participants whose photographs are included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data-sharing statement"}}]}}